

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231,

On

November 8, 2002

By

Julia K. Mause

Attorney Docket No. 0228us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Poul Baad Rasmussen, et al.

Application No.: **10/084,706**

Filed: **February 26, 2002**

For: **Interferon Beta-Like Molecules**

Examiner: **J. Seharaseyon**

Art Unit: **1647**

**INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR § 1.97 and § 1.98**

RECEIVED

NOV 15 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on the attached Forms PTO/SB/08A-B are being called to the attention of the Examiner, to make of record references cited in parent application USSN 09/648,569 filed August 25, 2000. Pursuant to 37 CFR § 1.98(d), copies of the references cited in parent application USSN 09/648,569 are not provided. However, Applicants will gladly provided fresh copies of any references requested by the Examiner.

It is respectfully requested that the information cited on the previously submitted Forms PTO/SB/08A-B for parent application USSN 09/648,569 be expressly considered during the prosecution of the present application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

It is believed that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Joanne R. Petithory
Reg. No. 42,995

Dated: Nov. 8, 2002

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COPY FROM PATENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Complete if Known

Application Number	09/648,569 - 10/084,706
Filing Date	August 25, 2000 Feb 26, 2002
First Named Inventor	A. H. Pedersen Rasmussen, P.B.
Group Art Unit	1647
Examiner Name	J. Seharaseyon
Attorney Docket Number	0202us810 - 0228us410

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,206,344		Katre et al.	04/27/1993	
	2	5,738,846		Greenwald et al.	04/14/1998	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	WO	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
	7	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998		
	8	WO	99/55377	A2	Applied Research Systems	11/04/1999		

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.	
	10	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/648,569 10/084 706
	Filing Date	August 25, 2000 02/26/02
	First Named Inventor	Anders Hjelholt Pedersen Rasmussen
	Group Art Unit	1639-1647
	Examiner Name	Unassigned J. Seharaseyon
	Attorney Docket Number	21-107600US 0228us410

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	4,769,233		Bell et al.	09-06-1988	
	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
	AF	4,917,888		Katre et al.	04-17-1990	
	AG	4,966,843		McCormick et al.	10-30-1990	
	AH	5,218,092		Sasaki et al.	08-06-1993	
	AI	5,376,567		McCormick et al.	12-27-1994	
	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
	AK	5,545,723		Goelz et al.	08-13-1996	
	AL	5,795,779		McCormick et al.	08-18-1998	

RECEIVED

NOV 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AM	WO	95/25170		Biogen, Inc.	09-21-1995		
	AN	WO	98/48018		Fraun-Hofer- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	WO	99/03887		Bolder Biotechnology	01-28-1999		
	AP	WO	99/55377		Applied Research	11-04-1999		
	AQ	WO	99/67291		Immunex Corporation	12-29-1999		
	AR	WO	00/23114		Biogen, Inc.	04-27-2000		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PARENT

Institute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/648,569- 10/084,706
Filing Date	August 25, 2000 02/26/02
First Named Inventor	Anders Hjelholt Pedersen Rasmussen
Group Art Unit	1633-1647
Examiner Name	Unassigned J. Seharaseyon
Attorney Docket Number	31-107600US- 0228 US 410

AS	WO	00/23472	Biogen, Inc.	04-27-2000	
AT	WO	00/26354	Novo Nordisk	05-11-2000	
AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	
AV	EP	041 313	Biogen, Inc.	09-12-1990	
AW	EP	229 108	Cetus Corporation	12-27-1990	
AX	EP	260 350	Cetus Corporation	02-12-1992	
AY	EP	287 075	Arzeneimittelforschung /Drug Research	01-18-1995	
AZ	EP	539 300	Philippe Thiriet	02-07-1996	
BA	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998	

RECEIVED

NOV 15 2002


TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	BB	Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β " <u>Cancer Immunol Immunother</u> (1994) 39:263-268	
	BC	Karpusas et al., "The Structure of Human Interferon- β : Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas et al. "The crystal structure of human interferon β at 2.2 A resolution" <u>Proc. Nat. Acad. Sci. USA</u> (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" <u>Int. Arch. Allergy Immunol</u> 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" <u>Clinical Therapeutics</u> vol. 19, No. 5, 1997 883-893	
	BG	Redlich et al., "Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <u>Proc. Natl. Acad. Sci. USA</u> vol. 88, pp. 4040-4044 May 1991	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/648,569 10/084,706
Filing Date	August 25, 2000 02/26/02
First Named Inventor	Anders Hjelholt Pedersen Rasmussen
Group Art Unit	1633 1647
Examiner Name	Unassigned J. Seharaseyon
Attorney Docket Number	31-107600US 0228US410

BH	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis" <u>Neurology</u> May 1889, 50: 1266-1272
BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)" <u>Pharmaceutical Research</u> vol. 15, No 4, 1998, 641-649
BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" <u>J. Mol. Biol.</u> (1995) 253, 187-207
BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- β : Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128
BM	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" <u>Gene</u> 10 (1980) 11-15
BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" <u>Neurology</u> 1998; 51: 682-689

RECEIVED
NOV 15 2002
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.